NCT07011719View on ClinicalTrials.gov

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

PHASE3RecruitingINTERVENTIONAL
Enrollment

720

Participants

Timeline

Start Date

September 8, 2025

Primary Completion Date

April 30, 2028

Study Completion Date

December 31, 2030

Conditions
Metastatic Clear Cell Renal Cell CarcinomaAdvanced Clear Cell Renal Cell Carcinoma
Interventions
DRUG

Casdatifan

Administered as specified in the treatment arm

DRUG

Cabozantinib

Administered as specified in the treatment arm

DRUG

Placebo

Administered as specified in the treatment arm

Trial Locations (5)

30265

NOT_YET_RECRUITING

City of Hope Cancer Center Atlanta, Newnan

30318

NOT_YET_RECRUITING

Piedmont Cancer Institute OneOncology, Atlanta

60099

NOT_YET_RECRUITING

City of Hope - Chicago Cancer Center, Zion

85338

NOT_YET_RECRUITING

City of Hope - Phoenix Cancer Center, Goodyear

91010

RECRUITING

City Of Hope National Medical Center, Duarte

Sponsors
All Listed Sponsors
lead

Arcus Biosciences, Inc.

INDUSTRY